Literature DB >> 1116418

Treatment of phenothiazine induced bulbar persistent dyskinesia with deanol acetamidobenzoate.

D J Curran, S Nagaswami, K J Mohan.   

Abstract

The late manifestation of neuroleptic-induced dyskinesia (persistent dyskinesia) is an irreversible complication of long-term treatment that is poorly understood and difficult to treat. Recently, a theory of dopamine receptor hypersensitivity in the dopaminergic-cholinergic system has suggested an explanation of choreiform movements and, thus, an implication for the management of persistent dyskinesia. The case presented is that of bulbar persistent dyskinesia in a patient who had been prescribed a phenothiazine derivative for eleven years; his symptoms improved with the use of deanol, which probably converts to acetylcholine after crossing the blood brain barrier. This improvement suggests that deanol may shift the neuroleptic-induced dopaminergic-cholinergic system unbalance toward equilibrium by matching predominant dopaminergic effect or by enhancing deficient cholinergic action in the dopaminergic-cholinergic system. This isolated finding needs to be confirmed by more research in neuropharmacology.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1116418

Source DB:  PubMed          Journal:  Dis Nerv Syst        ISSN: 0012-3714


  4 in total

1.  What's new in the psychopharmacology of schizophrenia.

Authors:  A Rifkin; F Quitkin
Journal:  Bull N Y Acad Med       Date:  1978-10

2.  [Deanol in tardive dyskinesia: a double-blind study (author's transl)].

Authors:  S Bockenheimer; G Lucius
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1976-09-17

3.  Deanol in the treatment of tardive dyskinesia.

Authors:  G M Simpson; A Voitashevsky; M A Young; J H Lee
Journal:  Psychopharmacology (Berl)       Date:  1977-05-09       Impact factor: 4.530

Review 4.  Cholinergic medication for antipsychotic-induced tardive dyskinesia.

Authors:  Irina Tammenmaa-Aho; Rosie Asher; Karla Soares-Weiser; Hanna Bergman
Journal:  Cochrane Database Syst Rev       Date:  2018-03-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.